Should We Care About Subclinical Primary Sclerosing Cholangitis with Inflammatory Bowel Disease?

A recent study (AK Lunder et al. Gastroenterol 2016; 151: 660-69, editorial 590-3) provides more information about the prevalence of subclinical primary sclerosing cholangitis (PSC) in the setting of long-term inflammatory bowel disease. From a cohort of 756 Norwegian patients in the “IBSEN” cohort of patients with inflammatory bowel disease, the authors analyzed 327 patients with magnetic resonance cholangiography (MRC).

Key findings:

  • 24 (7.5%) of 327 patients who had been followed for 20 years were found to have PSC lesions.  Only 7 (2.2%) were known to have PSC based on biochemical or clinical features. Subsequently, a missed case of small-duct PSC was recognized increasing the rate to 8.1%.
  • Subclinical PSC, interestingly, was detected more often in Crohn’s patients (9.0%) compared with ulcerative colitis (6.8%)
  • Extensive colitis, high prevalence of colectomy, and refractory IBD symptoms were more common in patients with suspected PSC compared with those without PSC features (P= .029, P= .002, and P= .012 respectively)

The natural history of these subclinical cases of PSC is unclear.  Studies have shown that patients with PSC with normal alkaline phosphatase values have an excellent outlook.  Yet, there should be some concern.  PSC has been associated with 400-fold higher chance of cholangiocarcinoma and 5-fold increased risk of developing colorectal cancer.  This could indicate the need for more intensive surveillance in these patients –though the exact risks in those with subclinical disease is unknown.

My take: Until we know more, I doubt looking for subclinical PSC makes sense outside research protocols.

Related blog posts:


7 thoughts on “Should We Care About Subclinical Primary Sclerosing Cholangitis with Inflammatory Bowel Disease?

  1. Pingback: Primary Sclerosing Cholangitis (PSC) –Natural History Study | gutsandgrowth

  2. Pingback: Liver Problems with Inflammatory Bowel Disease | gutsandgrowth

  3. Pingback: Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis | gutsandgrowth

  4. Pingback: Easy Advice for Pediatric Hepatologists: PSC Surveillance Recommendations | gutsandgrowth

  5. Pingback: Development of Primary Sclerosing Cholangitis in Pediatric Patients with Inflammatory Bowel Disease | gutsandgrowth

  6. Pingback: Online Aspen Webinar (Part 3) -Primary Sclerosing Cholangitis | gutsandgrowth

  7. Pingback: How Primary Sclerosing Cholangitis Alters Outcomes in Inflammatory Bowel Disease | gutsandgrowth

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.